**Research Area:** 

# Non-Small Cell Lung Cancer

Sotorasib\* (AMG 510) \*Proposed INN CodeBreak

- Amgen Study: 20190009
- NCT: 04303780
- EudraCT: 2019-003582-18


A Phase 3 Multicenter, Randomized, Open Label, Active-Controlled, Study of Sotorasib Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic Non-Small Cell Lung Cancer (NSCLC) Subjects with Mutated *KRAS p.G12C* 

### Primary Endpoint:

• Progression-free survival (PFS)

#### **Secondary Endpoints:**

- OS, ORR, DOR, TTR, DCR
- Quality of life assessment, PRO
- · Safety and tolerability
- PK



#### **Key Inclusion Criteria:**

- Adults with pathologically documented, previously treated, locally-advanced and unresectable or metastatic NSCLC with *KRAS p.G12C* mutation confirmed through molecular testing
- ECOG PS  $\leq 1$
- ≤ 1 prior systemic therapy including platinum-based doublet chemotherapy and checkpoint inhibitor

#### **Key Exclusion Criteria:**

- Active brain metastases
- Prior docetaxel treatment
- Gastrointestinal tract disease causing the inability to take oral medication
- Major surgery within 28 days of study day 1

DCR, disease control rate; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; INN, international nonproprietary name; *KRAS*, Kirsten rat sarcoma viral oncogene homolog; ORR, objective response rate; OS, overall survival; PK, pharmacokinetics; PRO, patient-reported outcomes; Q3W, every 3 weeks; QD, every day; R, randomization; TTR, time to response.

Product has not been authorised by regulatory agencies for marketing and is only authorised for investigational use in this trial.



Oncology

## Sotorasib

#### **Key Summary Points:**

CodeBreak 200 is a Phase 3 study to compare sotorasib to docetaxel for the treatment of subjects with previously treated locally advanced and unresectable or metastatic non-small cell lung cancer (NSCLC) with mutated *KRAS p.G12C*.

The primary outcome measure is progression-free survival (PFS) defined as time from randomization until disease progression or death from any cause, whichever occurs first.

#### **Additional Information:**

• www.clinicaltrials.gov Identifier - NCT: 04303780

CodeBreak

200

- www.amgentrials.com Protocol Number: 20190009
- www.clinicaltrialsregister.eu EudraCT: 2019-003582-18

Amgen (Europe) GmbH, 6343 Rotkreuz, Switzerland Date of preparation: June 2020 SC-EU-AMG 150-00046 © 2020 Amgen Inc. All rights reserved.

